Watch VRCA. Know when insiders buy.
One email the day a filing lands. Free.
VRCA
Verrica Pharmaceuticals Inc.
4.38
−0.13 −2.99%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $75.2MP/E —DIV YIELD —FCF YIELD —REV TTM $30.3M +106.2%NET INCOME −$31.2MNET CASH $11.2M52W 3.28 – 9.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $5.9M | −53.8% | — | −$13.1M | −$13.2M | −6547.5% | -0.62 | −$9.3M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $5M | +46.1% | — | −$9.7M | −$9.7M | — | -0.45 | −$9.2M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $5.1M | +1380.2% | — | −$7.2M | −$8.1M | — | -0.65 | −$4.6M | $0 | −$4.6M | Mar 11 |
| Q3 2025 · Sep 30 | $14.3M | — | — | $1.6M | −$274K | — | -0.03 | $9.7M | $0 | $9.7M | Nov 14 |
| Q2 2025 · Jun 30 | $12.7M | +145.4% | — | $1.5M | $204K | — | 0.02 | −$10M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $3.4M | −10.1% | 79.6% | −$8.1M | −$9.7M | — | -1.03 | −$12.7M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $344K | −82.7% | -132.6% | −$11.4M | −$16.2M | — | -1.82 | −$16.1M | $0 | −$16.1M | Mar 11 |
| Q3 2024 · Sep 30 | −$1.8M | −161.1% | 122.5% | −$20.7M | −$22.9M | — | -4.88 | −$8.6M | $16K | −$8.6M | Nov 14 |
| Q2 2024 · Jun 30 | $5.2M | — | 86.5% | −$15.2M | −$17.2M | — | -3.70 | −$16.4M | $11K | −$16.4M | Nov 14 |
| Q1 2024 · Mar 31 | $3.8M | — | 81.7% | −$18.6M | −$20.3M | — | -0.44 | −$19.9M | $0 | −$19.9M | Nov 14 |
| Q4 2023 · Dec 31derived | $2M | — | 89.9% | −$23.1M | −$24.6M | — | -0.54 | −$14.5M | $227K | −$14.7M | Mar 11 |
| Q3 2023 · Sep 30 | $2.9M | — | 89.7% | −$23.9M | −$24.8M | — | -0.54 | −$14.8M | $65K | −$14.9M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $35.6M | — | −$12.2M | −$17.9M | -50.3% | -1.68 | −$17.6M | $0 | −$17.6M | — | — |
| FY2024 · to Dec 31 | $7.6M | 65.6% | −$65.9M | −$76.6M | -1012.1% | -14.78 | −$60.9M | $27K | −$61M | — | — |
| FY2023 · to Dec 31 | $5.1M | 90.2% | −$65.8M | −$67M | -1307.5% | -1.48 | −$38.6M | $362K | −$38.9M | — | — |
| FY2022 · to Dec 31 | $9M | — | −$21.3M | −$24.5M | -271.1% | -0.72 | −$18.6M | $302K | −$19M | — | — |
| FY2021 · to Dec 31 | $12M | — | −$30.9M | −$35.1M | -292.3% | -1.30 | −$27.6M | $883K | −$28.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$40.2M | −$42.7M | — | -1.71 | −$30.2M | $1.5M | −$31.7M | — | — |
Every number comes from Verrica Pharmaceuticals Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.